GlaxoSmithKline News and Research

RSS

GlaxoSmithKline to pursue novel antibacterial research program for DOD

GlaxoSmithKline has announced that it has signed an agreement with the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD), to identify and develop a new class of antibacterials targeting both Gram negative biothreats and conventional Gram negative hospital pathogens.

18 Sep 2007

GlaxoSmithKline responds to Journal of the American Medical Association articles

GlaxoSmithKline believes that conclusions drawn from the most recent meta-analyses published by Drs. Nissen et. al. and Furberg et. al. in the Journal of the American Medical Association do not confirm a difference in the safety profile of Avandia (rosiglitazone) and Actos (pioglitazone).

12 Sep 2007

GSK supports emphasis on asthma control in treatment guidelines

New asthma treatment guidelines issued today urge healthcare professionals to first assess the severity of a patient's asthma to determine and administer initial treatment and then obtain regular assessments of the patient's level of asthma control.

29 Aug 2007

Effects of obesity on egg and infertility discovered

A researcher at the University of Adelaide, Australia, has discovered scientific evidence that obesity is a key factor in infertility – because of how it affects women's eggs.

24 Aug 2007

Strengthened warnings on some type 2 diabetes drugs

The U.S. Food and Drug Administration has announced manufacturers of certain drugs approved to treat Type 2 diabetes have agreed to add a stronger warning on the risk of heart failure, a condition that occurs when the heart does not adequately pump blood.

16 Aug 2007

Rotarix accepted for review by FDA

GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for Rotarix, an oral candidate vaccine for infants to prevent rotavirus gastroenteritis.

16 Aug 2007

Writing off Avandia may be premature

Rosiglitazone, a drug marketed by GlaxoSmithKline as Avandia, for the treatment of type 2 diabetes, came under fire after an article published online May 21 by the New England Journal of Medicine linked it to significantly increased risk of heart attack and cardiovascular death.

12 Aug 2007

GSK receives FDA 'not approvable letter' for Advair for COPD

GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has issued a not approvable letter for the supplemental drug application for the 500/50 strength of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in the treatment of patients with chronic obstructive pulmonary disease (COPD).

9 Aug 2007

U.S. stocks up again on bird flu vaccine

The Department of Health and Human Services in the United States has ordered more doses of the avian flu vaccine from the international pharmaceutical giant GlaxoSmithKline (GSK).

7 Aug 2007

GlaxoSmithKline receives bulk H5N1 antigen order for the US national stockpile

GlaxoSmithKline has announced that HHS has placed another order to purchase bulk H5N1 antigen for the US national stockpile of pre-pandemic vaccines.

6 Aug 2007

Worldwide distribution of cervical cancer virus is consistent with vaccine targets

The variety of human papilloma viruses that cause invasive cervical cancer cases worldwide are largely consistent across continents, according to a new study from the University of North Carolina at Chapel Hill.

3 Aug 2007

Biota increases damages claim against GlaxoSmithKline

Australian company Biota has filed its updated Particulars of Loss and Damage in its suit against GlaxoSmithKline (GSK) for failing to support the influenza drug, Relenza, discovered by Biota and licensed to GSK in 1990.

31 Jul 2007

Majority of FDA panel votes in favor of Avandia

GlaxoSmithKline has welcomed the nearly unanimous recommendation of an U.S. Food and Drug Administration's (FDA) advisory committee to support Avandia's (rosiglitazone maleate) continued availability to patients in the U.S.

30 Jul 2007

Takeda responds to FDA recommendation on Actos

Following a joint meeting today of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development (TGRD) underscores its position that ACTOS(R) (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease.

30 Jul 2007

Ranbaxy and GSK agree to settle Valacyclovir U.S. patent case

Ranbaxy Laboratories Limited (RLL) announced today that the Company has reached an agreement with GlaxoSmithKline (GSK) resulting in a dismissal of their U.S. litigation with regard to Valtrex(R) (Valacyclovir Hydrochloride tablets).

27 Jul 2007

Initiative to improve heart failure care at nation's hospitals makes major gains

A national initiative designed to improve heart-failure patient care in hospitals proved effective at increasing hospital adherence to key quality-of-care performance measures and reducing the length of hospital stays for patients.

24 Jul 2007

GSK's Cervarix receives positive opinion in Europe

GlaxoSmithKline has announced that its cervical cancer candidate vaccine received a positive opinion from the European Committee for Human Medicinal Products (CHMP) for the prevention of precancerous lesions (high grade cervical intraepithelial neoplasia - CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus types 16 and 18.

19 Jul 2007

Review of Rosiglitazone for type 2 diabetes mellitus

Little evidence supports using rosiglitazone (Avandia) to improve the quality or length of life among adults with diabetes, according to a systematic review of data by German researchers.

18 Jul 2007

Alli jokes - great marketing!

GlaxoSmithKline's new diet drug, Alli, hit shelves nationwide last month.

4 Jul 2007

Trial shows CERVARIX cervical cancer candidate vaccine effective

Results from an interim analysis of a Phase III study show that CERVARIX, the GlaxoSmithKline (GSK) cervical cancer candidate vaccine, provides up to 100 percent protection against advanced precancerous lesions caused by the most common types of human papillomavirus, types 16 and 18.

28 Jun 2007